Smoking is the main environmental risk while HLA-DR4 constitutes the main genetic risk factor. In developed populations, the prevalence rate of RA is approximately 0.5% to 1% of the adult population. The goal of treatment is to improve pain, decrease inflammation, and improve a person's overall functioning. Non-steroidal antiinflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), steroids may be used for pain management and slow the progression of the disease. Surgical management may be indicated to repair or replace joints in advanced stages.
Mesenchymal progenitor cells (MSCs) have been shown to have immunoregulatory, anti-inflammatory and tissue repairing properties. Treatment with these cells is a feasible, safe, and promising treatment modality for patients with RA.
Our protocol involves harvesting cells from the patients own body (autologous stem cells). After activation the cells are transplanted into the appropriate site. The degree of improvement achieved will depend on the stage of the condition, presence of other influencing factors and patient compliance with respect to following diet and allied therapies (physiotherapy, yoga).